Cytox launches its first direct to consumer social media awareness campaign on behalf of Sampled Smart Labs
Our in-house marketing team has carried out market research to learn more about consumers’ interest in understanding the risk of developing Alzheimer’s disease. For many, the desire stems from seeing a relative with the condition, while for others there is concern that a loved one may be exhibiting symptoms or a wish to be proactive about their long-term health. With this information, Cytox on behalf of Sampled Smart Labs, Piscataway, New Jersey has initiated a multi-channel campaign to make consumers aware that not only is it possible to assess each person’s individual risk, but there are ways to prevent or take control of their wellbeing. Using social media and Google tools, the campaign is reaching millions of US consumers around the network of clinics that are offering the Alzheimer’s Risk Test, developed by Sampled Smart Labs, powered by genoSCORE™. As well as being educational and informative, the campaign enables anyone interested in receiving the test to be directed to their nearest clinic. Since its launch, over 500 consumers have been connected to a healthcare professional who can help answer their questions and provide reassurance and guidance.
About Cytox (www.cytoxgroup.com)
Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease (AD) - is estimated to exceed $1tn per year in the next decade2. AD – a highly complex disease with risk factors based in genetics, lifestyle, age, and environment. Cytox’s products technology genoSCORE™ and genoTOR™ use Polygenic Risk Scoring (PRS) to predict the risk of individuals developing AD, and to improve clinical trial outcomes through patient stratification and the genetic characterisation of the disease.
The genoSCORE technology underpins non-invasive, genetic tests to assess the risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) - small genetic variations - that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS).
Developers of new AD drug therapies can also the test to identify and recruit patients to clinical studies, ensuring the selection of the most suitable candidates, those most likely to experience cognitive decline over the time period of the study.
About Alzheimer’s Risk Test
In the United States, Sampled Smart Labs, Piscataway, New Jersey have developed the Alzheimer’s Risk Test, powered by genoSCORE™
Clinicians can use the test to assess patients for the risk of developing Alzheimer's disease, before symptoms arise, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use would enable elderly and vulnerable patients self-isolating due to COVID-19, or not wishing or easily able to attend healthcare settings, to provide a suitable sample from home.